financetom
Business
financetom
/
Business
/
Update: UGI Shares Rise Following Fiscal Q4 Results, Fiscal 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: UGI Shares Rise Following Fiscal Q4 Results, Fiscal 2025 Outlook
Nov 22, 2024 9:41 AM

12:22 PM EST, 11/22/2024 (MT Newswires) -- (Updates to include recent UGI stock movement in the headline and first paragraph.)

UGI (UGI) shares were up more than 14% in recent Friday trading after it issued fiscal 2025 adjusted earnings per share guidance, with the upper end above market expectations.

The company reported a fiscal Q4 net loss late Thursday of $1.27 per diluted share, compared with income of $0.61 a year earlier.

One analyst polled by FactSet expected a $0.26 loss.

Revenue for the quarter ended Sept. 30 fell to $1.24 billion from $1.40 billion a year earlier.

One analyst surveyed by FactSet expected $1.65 billion.

For fiscal 2025, the company expects adjusted EPS of $2.75 to $3.05. Three analysts polled by FactSet expect $2.95.

Price: 28.42, Change: +3.64, Percent Change: +14.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neurocrine Biosciences' Huntington's disease drug gets FDA approval (April 30)
Neurocrine Biosciences' Huntington's disease drug gets FDA approval (April 30)
May 1, 2024
April 30 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' ( NBIX ) Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline...
Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court
Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court
May 1, 2024
May 1(Reuters) - A Washington state appeals court on Wednesday overturned a $185 million verdict against Bayer's Monsanto unit over chemical contamination at a Seattle-area school, marking the second big legal win for the company in as many weeks. Monsanto spinoff Pharmacia, which sold now-banned chemicals called polychlorinated biphenyls, was found liable in 2021. Three teachers claimed they suffered brain...
DBS sees net profit rising this year after Q1 beats forecasts
DBS sees net profit rising this year after Q1 beats forecasts
May 1, 2024
By Yantoultra Ngui SINGAPORE (Reuters) -Singapore's biggest bank DBS Group expects its net profit to grow this year, it said on Thursday, after posting a 15% rise in first quarter net profit that beat expectations, driven by strong total income growth. While geopolitical tensions persist, macroeconomic conditions remain resilient and our franchise is well positioned to capture business opportunities, DBS...
Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court
Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court
May 1, 2024
(Reuters) - A Washington state appeals court on Wednesday overturned a $185 million verdict against Bayer's Monsanto unit over chemical contamination at a Seattle-area school, marking the second big legal win for the company in as many weeks. Monsanto spinoff Pharmacia, which sold now-banned chemicals called polychlorinated biphenyls, was found liable in 2021. Three teachers claimed they suffered brain damage...
Copyright 2023-2026 - www.financetom.com All Rights Reserved